Efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial.

IF 3 3区医学 Q1 OPHTHALMOLOGY

Acta Ophthalmologica Pub Date : 2024-08-21 DOI:10.1111/aos.16750

Wenqing Ye, Jinxing Li, Shaodan Zhang, Shuqing Zhu, Yanqian Xie, Rongrong Le, Weihe Zhou, Mingguang He, Ningli Wang, Yuanbo Liang

{"title":"Efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for primary open-angle glaucoma: A randomized controlled trial.","authors":"Wenqing Ye, Jinxing Li, Shaodan Zhang, Shuqing Zhu, Yanqian Xie, Rongrong Le, Weihe Zhou, Mingguang He, Ningli Wang, Yuanbo Liang","doi":"10.1111/aos.16750","DOIUrl":null,"url":null,"abstract":"Purpose: To report the 2-year efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for the treatment of primary open-angle glaucoma (POAG).Setting: A single surgical site in China.Design: This was a prospective, randomized controlled trial. POAG patients were randomly assigned to the penetrating canaloplasty or ab externo canaloplasty group.Methods: This study enrolled POAG patients who underwent penetrating canaloplasty or ab externo canaloplasty randomly. Surgical success, intraocular pressure (IOP), number of glaucoma medications, and surgical complications were evaluated until 24 months post-operatively. Surgical success was defined as 6 mmHg ≤ IOP ≤21 mmHg with an IOP reduction ≥20%, which included qualified success (with or without medications) and complete success (without medications).Results: A total of 52 eyes (45 patients) were randomly assigned to one of two groups: the penetrating canaloplasty group (PCP, n = 26) or the ab externo canaloplasty group (CP, n = 26). The probabilities of qualified success and complete success were 92.3% and 76.9%, respectively, in the PCP group and 64.1% and 52.1%, respectively, in the CP group at 24 months (p = 0.013, p = 0.042, log-rank test). The mean IOP decreased from 30.8 ± 10.7 and 28.6 ± 11.8 mmHg to 14.1 ± 3.3 mmHg in the PCP group and 22.1 ± 13.6 mmHg in the CP group at year two (p = 0.007). The PCP group also received fewer medications (0.2 ± 0.5) than did the CP group (0.7 ± 1.2) at year two (p = 0.038). Post-operative complications were similar, and the most common complications were transient IOP elevation and hyphema in the PCP group (42.3%, 46.2%) and the CP group (38.5%, 23.1%) (p > 0.05).Conclusions: Compared to ab externo canaloplasty, penetrating canaloplasty had a greater surgical success rate and better IOP reduction with a comparable rate of complications.","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aos.16750","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report the 2-year efficacy and safety of penetrating canaloplasty versus ab externo canaloplasty for the treatment of primary open-angle glaucoma (POAG).

Setting: A single surgical site in China.

Design: This was a prospective, randomized controlled trial. POAG patients were randomly assigned to the penetrating canaloplasty or ab externo canaloplasty group.

Methods: This study enrolled POAG patients who underwent penetrating canaloplasty or ab externo canaloplasty randomly. Surgical success, intraocular pressure (IOP), number of glaucoma medications, and surgical complications were evaluated until 24 months post-operatively. Surgical success was defined as 6 mmHg ≤ IOP ≤21 mmHg with an IOP reduction ≥20%, which included qualified success (with or without medications) and complete success (without medications).

Results: A total of 52 eyes (45 patients) were randomly assigned to one of two groups: the penetrating canaloplasty group (PCP, n = 26) or the ab externo canaloplasty group (CP, n = 26). The probabilities of qualified success and complete success were 92.3% and 76.9%, respectively, in the PCP group and 64.1% and 52.1%, respectively, in the CP group at 24 months (p = 0.013, p = 0.042, log-rank test). The mean IOP decreased from 30.8 ± 10.7 and 28.6 ± 11.8 mmHg to 14.1 ± 3.3 mmHg in the PCP group and 22.1 ± 13.6 mmHg in the CP group at year two (p = 0.007). The PCP group also received fewer medications (0.2 ± 0.5) than did the CP group (0.7 ± 1.2) at year two (p = 0.038). Post-operative complications were similar, and the most common complications were transient IOP elevation and hyphema in the PCP group (42.3%, 46.2%) and the CP group (38.5%, 23.1%) (p > 0.05).

Conclusions: Compared to ab externo canaloplasty, penetrating canaloplasty had a greater surgical success rate and better IOP reduction with a comparable rate of complications.

查看原文本刊更多论文

原发性开角型青光眼穿透性虹膜睫状体成形术与外虹膜睫状体成形术的疗效和安全性对比：随机对照试验。

目的：报告在治疗原发性开角型青光眼（POAG）时，穿透性虹膜睫状体成形术与虹膜外虹膜睫状体成形术的两年疗效和安全性：中国的一个手术点：设计：这是一项前瞻性随机对照试验。POAG患者被随机分配到穿透性人工晶体植入术组或ab外人工晶体植入术组：方法：本研究纳入的 POAG 患者随机接受穿透性人工晶体植入术或人工晶体植入术。对手术成功率、眼压（IOP）、青光眼用药次数和手术并发症进行评估，直至术后 24 个月。手术成功定义为 6 mmHg ≤ IOP ≤ 21 mmHg，眼压降低≥20%，包括合格成功（使用或不使用药物）和完全成功（不使用药物）：共有 52 只眼睛（45 名患者）被随机分配到两组中的一组：穿透性管成形术组（PCP，n = 26）或体外管成形术组（CP，n = 26）。24 个月时，PCP 组的合格成功率和完全成功率分别为 92.3% 和 76.9%，CP 组分别为 64.1% 和 52.1%（p = 0.013，p = 0.042，log-rank 检验）。在第二年，PCP 组的平均眼压从 30.8 ± 10.7 mmHg 和 28.6 ± 11.8 mmHg 降至 14.1 ± 3.3 mmHg，CP 组的平均眼压从 22.1 ± 13.6 mmHg 降至 14.1 ± 3.3 mmHg（p = 0.007）。在第二年，PCP 组接受的药物治疗（0.2 ± 0.5）也少于 CP 组（0.7 ± 1.2）（p = 0.038）。术后并发症相似，PCP 组（42.3%，46.2%）和 CP 组（38.5%，23.1%）最常见的并发症是一过性眼压升高和眼底出血（P > 0.05）：结论：与ab externo 管成形术相比，穿透性管成形术的手术成功率更高，眼压降低效果更好，并发症发生率相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.